- Home
- JAZZ vs ITCI Comparison
JAZZ vs ITCI Comparison
Compare JAZZ & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- ITCI
- Stock Information
- Founded
- JAZZ 2003
- ITCI 2002
- Country
- JAZZ Ireland
- ITCI United States
- Employees
- JAZZ N/A
- ITCI N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- JAZZ Health Care
- ITCI Health Care
- Exchange
- JAZZ Nasdaq
- ITCI Nasdaq
- Market Cap
- JAZZ 6.5B
- ITCI 8.0B
- IPO Year
- JAZZ 2007
- ITCI N/A
- Fundamental
- Price
- JAZZ $113.09
- ITCI $86.40
- Analyst Decision
- JAZZ Buy
- ITCI Strong Buy
- Analyst Count
- JAZZ 14
- ITCI 12
- Target Price
- JAZZ $173.43
- ITCI $97.00
- AVG Volume (30 Days)
- JAZZ 496.2K
- ITCI 459.9K
- Earning Date
- JAZZ 11-06-2024
- ITCI 10-30-2024
- Dividend Yield
- JAZZ N/A
- ITCI N/A
- EPS Growth
- JAZZ N/A
- ITCI N/A
- EPS
- JAZZ 5.93
- ITCI N/A
- Revenue
- JAZZ $3,909,883,000.00
- ITCI $564,526,000.00
- Revenue This Year
- JAZZ $7.38
- ITCI $46.60
- Revenue Next Year
- JAZZ $6.87
- ITCI $37.06
- P/E Ratio
- JAZZ $18.79
- ITCI N/A
- Revenue Growth
- JAZZ 3.91
- ITCI 54.31
- 52 Week Low
- JAZZ $99.06
- ITCI $46.10
- 52 Week High
- JAZZ $134.48
- ITCI $84.89
- Technical
- Relative Strength Index (RSI)
- JAZZ 52.57
- ITCI 73.36
- Support Level
- JAZZ $107.44
- ITCI $75.57
- Resistance Level
- JAZZ $112.55
- ITCI $79.46
- Average True Range (ATR)
- JAZZ 2.52
- ITCI 2.42
- MACD
- JAZZ -0.11
- ITCI 0.60
- Stochastic Oscillator
- JAZZ 40.87
- ITCI 88.13
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.